Loading clinical trials...
Loading clinical trials...
Safety and Efficacy of Polyclonal Antibodies in Simultaneous Pancreas Kidney Transplant Recipients: Single-centre, Prospective, Observational Study
Conditions
Interventions
Anti-Tlymphocyte Globulins
Anti-Thymocyte Globulins
Locations
1
China
Tianjin First central hospital
Tianjin, China
Start Date
March 1, 2018
Primary Completion Date
March 1, 2021
Completion Date
March 1, 2021
Last Updated
March 20, 2018
NCT00001987
NCT07051005
NCT07480161
NCT04786262
NCT06748963
NCT06887049
Lead Sponsor
Tianjin First Central Hospital
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions